A federal lawsuit filed by the FTC against CellMark Biopharma, LLC resulted in the company being permanently blocked from making deceptive claims related to two of their health products. CellMark Biopharma advertised these products as an effective treatment for malnutrition, “chemo fog,” and other cognitive dysfunctions caused by cancer treatment.
FTC: CellMark Used Unsupported Scientific Claims Related to Their Products
The FTC alleged in their complaint that CellMark Biopharma, LLC used unsupported scientific claims when they marketed CellAssure and Cognify as a “medical breakthrough” with “anti-cancer and anti-tumor properties” (paragraph 11).
Copies of the advertisements are attached to the complaint and listed as Exhibits 1 through 4-B. CellAssure is listed as a “medical nutrition drink” with “clinically proven ingredients” that were “scientifically formulated to deliver an unheard of level of health, protection and quality of life of rour patients.” CellAssure is also advertised as a way to “promote a healthy immune response.”
